Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Systemic Absorption of H-1337 in Healthy Volunteers
NCT06572397Phase 1Completed
- Sponsor
- D. Western Therapeutics Institute
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of H-1337 in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by D. Western Therapeutics Institute. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at Day 9. Started Sep 2024; status: completed.
02
Drugs
H-1337
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT06572397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572397.